Glucocorticosteroids differentially regulate MMP-9 and neutrophil elastase in COPD

Area of Science:

• Pulmonary Medicine
• Inflammation Research
• Biochemistry

Background:

• Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of death, characterized by neutrophilic inflammation.
• Neutrophil-derived proteinases, matrix metalloproteinase-9 (MMP-9) and neutrophil elastase (NE), contribute to COPD pathogenesis.
• Glucocorticosteroids (GCs) are often ineffective in managing this inflammation.

Purpose of the Study:

• To investigate the role of neutrophil activation and proteinase release in COPD severity.
• To explore the regulation of MMP-9 and NE by GCs and potential alternative pathways.

Main Methods:

• Stratified MMP-9 and NE activity in bronchoalveolar lavage fluid (BALF) by GOLD severity.
• Examined NE and MMP-9 regulation in isolated neutrophils using pharmacological inhibitors.
• Investigated in vivo proteinase release in mice exposed to cigarette smoke (CS) and/or lipopolysaccharide (LPS) with dexamethasone (Dex).

Main Results:

• Neutrophil activation (NE release) and MMP-9 levels/activity significantly increased with COPD severity (GOLD II vs. IV).
• NE and MMP-9 release from stimulated neutrophils was insensitive to dexamethasone but inhibited by a PI3K inhibitor.
• Glucocorticosteroid-resistant neutrophil activation and MMP-9 expression were observed in mice exposed to CS and LPS.

Conclusions:

• Activated neutrophils are a key source of NE and MMP-9 in severe COPD, contributing to proteinase imbalance.
• The glucocorticosteroid resistance of NE and MMP-9 release highlights the PI3K pathway as a potential therapeutic target.
• Targeting the PI3K pathway may offer a novel strategy to manage proteinase dysregulation in severe COPD.